Stay updated on Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.

Latest updates to the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page has removed an erratum notice related to a clinical study on Tipifarnib in Head and Neck Squamous Cell Carcinoma, which may affect the accuracy of the information presented.SummaryDifference0.4%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check60 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed information about a Phase II study of tipifarnib for HRAS mutant tumors and the addition of a new version number, v2.15.0.SummaryDifference18%
Stay in the know with updates to Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.